These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18335161)

  • 21. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
    Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
    Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
    Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
    Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.
    Giannakis A; Chondrogiorgi M; Tsironis C; Tatsioni A; Konitsiotis S
    J Neural Transm (Vienna); 2018 Sep; 125(9):1341-1349. PubMed ID: 29352351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood levodopa levels and unified Parkinson's disease rating scale function: with and without exercise.
    Goetz CG; Thelen JA; MacLeod CM; Carvey PM; Bartley EA; Stebbins GT
    Neurology; 1993 May; 43(5):1040-2. PubMed ID: 8492923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations.
    Goetz CG; Pappert EJ; Blasucci LM; Stebbins GT; Ling ZD; Nora MV; Carvey PM
    Neurology; 1998 Feb; 50(2):515-7. PubMed ID: 9484386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
    Langdon N; Malcolm PN; Parkes JD
    Clin Neuropharmacol; 1986; 9(5):440-7. PubMed ID: 3768866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive Stress Reduces the Effect of Levodopa on Parkinson's Resting Tremor.
    Zach H; Dirkx MF; Pasman JW; Bloem BR; Helmich RC
    CNS Neurosci Ther; 2017 Mar; 23(3):209-215. PubMed ID: 28071873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.
    Del Bello F; Giannella M; Giorgioni G; Piergentili A; Quaglia W
    Biomolecules; 2019 Apr; 9(4):. PubMed ID: 30970612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill
    LeWitt PA; Giladi N; Navon N
    Parkinsonism Relat Disord; 2019 Aug; 65():131-138. PubMed ID: 31176632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perceived exertion and muscle efficiency in Parkinson's disease: L-DOPA effects.
    LeWitt PA; Bharucha A; Chitrit I; Takis C; Patil S; Schork MA; Pichurko B
    Clin Neuropharmacol; 1994 Oct; 17(5):454-9. PubMed ID: 9316695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease.
    Lees AJ
    Adv Neurol; 1990; 53():475-82. PubMed ID: 2239487
    [No Abstract]   [Full Text] [Related]  

  • 36. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corticotroph axis sensitivity after exercise in endurance-trained athletes.
    Duclos M; Corcuff JB; Arsac L; Moreau-Gaudry F; Rashedi M; Roger P; Tabarin A; Manier G
    Clin Endocrinol (Oxf); 1998 Apr; 48(4):493-501. PubMed ID: 9640417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
    Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M
    Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
    Zhang J; Tan LC
    Curr Neuropharmacol; 2016; 14(4):356-63. PubMed ID: 26644151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.